J&J Medical Connect
nipocalimab

Medical inquiries

Connect with my medical science liaison

Connect with my medical science liaison

Chat live

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Email your inquiry

Call 1-800-526-7736

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

nipocalimab

Medical Information

+ Save link

Nipocalimab – Use in Ocular Myasthenia Gravis

Last Updated: 12/20/2024

SUMMARY

  • Nipocalimab, a fully human, aglycosylated, effectorless immunoglobulin G1 (IgG1) anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody, is an investigational agent that is being studied for the treatment of generalized myasthenia  gravis (gMG) in adult and pediatric patients.1-3
  • There is no relevant data available regarding the use of nipocalimab in patients with ocular myasthenia gravis.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT® (and/or other resources, including internal/external databases) conducted on 26 November 2024 did not identify any relevant citations pertaining to this topic.

 

References

Show
1 Ramachandren S, Sanga P, Burcklen M, et al. Vivacity MG phase 3 study: clinical trial of nipocalimab administered to adults with generalized myasthenia gravis. Oral Presentation presented at: 8th European Academy of Neurology Congress; June 25-28, 2022; Vienna, Austria.  
2 Antozzi C, Guptill J, Bril V, et al. Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis. Neurology. 2024;102(2):e207937.  
3 Ramachandren S, Black S, Sun H, et al. Vibrance-mg: clinical trial of nipocalimab in pediatric myasthenia gravis. Poster presented at: American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting; September 21-24, 2022; Nashville, TN.